Dr Sarah Mitchell
banner
sarahmitchellphd.bsky.social
Dr Sarah Mitchell
@sarahmitchellphd.bsky.social

Staff Scientist @ Ludwig Princeton Branch

Engineering 40%
Political science 17%

Reposted by Sarah Mitchell

In our current Focus issue, #AgeingandCancer, Marco Demaria outlines how understanding the underlying molecular mechanisms of cancer treatment induced premature ageing-related conditions is crucial for developing integrated strategies to improve survivor health.
Cancer treatments accelerate ageing - Nature Reviews Cancer
While cancer treatments are essential for patient survival, they often induce premature ageing-related conditions in survivors. In this Comment, Demaria outlines how understanding the underlying molecular mechanisms of this is crucial for developing integrated strategies to improve long-term health outcomes in survivors.
bit.ly

“One man’s trash is another man’s treasure” 😬

Reposted by Sarah Mitchell

Reposted by Sarah Mitchell

US Biotech is #1.
And depends critically on academic research both for trained PhDs to wrestle cures from Nature and for curiosity-driven eurekas (eg CRISPR or statins).

Private industry will not be able to substitute for an enfeebled NIH.

We will have fewer cures and we will lose our primacy.

Reposted by Sarah Mitchell

Important and under-covered attack on the guts of NIH's intramural program from @science.org NIH ban on renewing senior scientists adds to assaults on its in-house research | Science | AAAS www.science.org/content/arti...
NIH ban on renewing senior scientists adds to assaults on its in-house research
Policy follows firings of tenure-track scientists and suspension of training programs
www.science.org

Reposted by Sarah Mitchell

New Research Network publication alert!

@sheehanmj.bsky.social and @matthewzipple.bsky.social, both recipients of Network Pilot & Feasibility awards, have published a paper in Aging Cell on ecological realism and epigenetic aging in mice. Congratulations, Mike and Matthew! doi.org/10.1111/acel...
Ecological Realism Accelerates Epigenetic Aging in Mice
Living environment shapes mammalian aging, but laboratory conditions lack the ecological realism of natural social, physical, and microbial environments. Comparing traditionally laboratory-reared and...
doi.org
A whole generation of early career scientists and physician-scientists, including colleagues and myself, are particularly vulnerable to these funding freezes and cuts, with jobs and careers depending on federal grants.

#IDsky
#Medsky
#Episky

www.science.org/content/arti...
U.S. early-career researchers struggling amid chaos
Uncertain funding, government firings, and distressed universities hit vulnerable groups especially hard
www.science.org

Reposted by Sarah Mitchell

AAV gene therapy for Cockayne syndrome
Cockayne Syndrome (CS) is an autosomal recessive, progressive developmental and neurodegenerative disease. Approximately 30% of cases are caused by mutations in the ERCC8/CSA gene. Patients with CS present with cutaneous photosensitivity, growth failure, shorter life span and a progressive degeneration of the central nervous system. Loss of function mutations in CSA result in deficiencies in transcription-coupled nucleotide excision repair, regulation of RNA Pol II mediated transcription repair of oxidative DNA damage, and mitochondrial metabolism. Currently there are no available therapies for these patients. AAV gene therapy offers an opportunity to address this unmet need. We designed a new AAV vector encoding human CSA under a CBA promoter. We tested the therapeutic efficacy of this AAV9-CSA vector by neonatal ICV injection in the Csa-/-;Xpa-/- mouse model. Treatment with AAV9-CSA resulted in a significant increase in lifespan, and broad distribution of human CSA in the brain and heart. Despite clear therapeutic benefit, we also observed neuroradiological abnormalities, neuropathologic alterations including hypo-myelination, astrocytosis, microgliosis, and likely life limiting transcriptomic alterations in liver at endpoint. Nonetheless, the success of these experiments paves the way for the first in human clinical translation of a gene therapy for CS patients. ### Competing Interest Statement The authors have declared no competing interest.
www.biorxiv.org

Super cool!

Reposted by Sarah Mitchell

Now online! Microbiome metabolism of dietary phytochemicals controls the anticancer activity of PI3K inhibitors
Microbiome metabolism of dietary phytochemicals controls the anticancer activity of PI3K inhibitors
Diet can impact anticancer drug activity. A classic example in rodents is a ketogenic diet enhancing PI3K inhibitor activity. Here, we show that phytochemicals and their microbiome derivatives, rather than macronutrient composition, underlie this phenomenon.
dlvr.it

Camilla is a horse face.

Wrong Sarah Mitchell!
Nothing will kill more children than the ongoing decimation of CDC, NIH, and USAID work to lift vaccine uptake in the US and world.

Child survival rose 75% in the last 50 years. Vaccines account for 40% of that. Measles vax alone was 60% of the benefit. www.thelancet.com/journals/lan...
Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization
Since 1974 substantial gains in childhood survival have occurred in every global region. We estimate that EPI has provided the single greatest contribution to improved infant survival over the past 50...
www.thelancet.com

Oooh that Elon felon one is good!

Reposted by Sarah Mitchell

... gait speed. Still better than anything molecular biomarkers can provide. Our commentary (with @regula-furrer.bsky.social @biozentrum.unibas.ch @unibas.ch) out now in NPJ Aging:

doi.org/10.1038/s415...

3/3
Biomarkers of aging: functional aspects still trump molecular parameters - npj Aging
Biomarkers of aging are indispensable for testing interventions. While promising, the recent focus on molecular aspects should not detract from the functional parameters for which excellent correlatio...
doi.org

Reposted by Sarah Mitchell

"When you hear about patients surviving stage 4 cancer because of immunotherapy, that was based on NIH research over many decades. When you hear about sickle cell disease being cured because of CRISPR gene editing, that was built on years of research supported by NIH"

apnews.com/article/nih-...
Renowned geneticist Francis Collins retires from NIH, urging 'respect' for embattled workers
Dr. Francis Collins, a renowned geneticist, and former longtime director of the National Institutes of Health, is retiring from the government agency and urging “respect” for its embattled workers.
apnews.com
Francis Collins, the NIH Director for 12 years, led the Human Genome Project and other NIH efforts for 32 years, resigned today. Key words from his resignation letter
www.nytimes.com/2025/03/01/u...

Shocking.
Important and under-covered attack on the guts of NIH's intramural program from @science.org NIH ban on renewing senior scientists adds to assaults on its in-house research | Science | AAAS www.science.org/content/arti...
NIH ban on renewing senior scientists adds to assaults on its in-house research
Policy follows firings of tenure-track scientists and suspension of training programs
www.science.org

Reposted by Sarah Mitchell

Happy to share this new #glycotime work with collaborator Tony Wyss-Coray, led by grad student Sophia Shi, mucin loss at the BBB is associated with aging and cognitive decline, can be reversed by restoration with with gene therapy. Aging is a mucinopathy!

www.nature.com/articles/s41...
Glycocalyx dysregulation impairs blood–brain barrier in ageing and disease - Nature
Disruption of mucin-domain glycoprotein expression and function in the endothelial glycocalyx are associated with ageing and Alzheimer’s disease, leading to dysregulated blood–brain barrier function.
www.nature.com

Reposted by Sarah Mitchell

Great to see AFAR! We need more of this! @afar.org

Reposted by Sarah Mitchell

NEWSY: The White House confirms tonight that Elon Musk is NOT the administrator of DOGE and is not even technically part of it.

He's a "senior adviser to the president" like Anita Dunn, they say. storage.courtlistener.com/recap/gov.us...

Reposted by Sarah Mitchell

Donald Trump and Elon Musk are trying to cut funding for cancer and rare disease research.

A federal judge temporarily blocked the cuts in some states, but this fight is not over.

We can’t let them play politics with our health.

This!!!!
US Biotech is #1.
And depends critically on academic research both for trained PhDs to wrestle cures from Nature and for curiosity-driven eurekas (eg CRISPR or statins).

Private industry will not be able to substitute for an enfeebled NIH.

We will have fewer cures and we will lose our primacy.
How much Elon Musk makes from the government a day: $8 million.

How much a senior on Social Security gets a day: $65

Guess which budget Musk and Trump want to cut?
Welcome to the Bluesky account for Stand Up for Science 2025!

Keep an eye on this space for updates, event information, and ways to get involved. We can't wait to see everyone #standupforscience2025 on March 7th, both in DC and locations nationwide!

#scienceforall #sciencenotsilence

Reposted by Sarah Mitchell

Government isn't a business. The goal isn't to save money. Success isn't measured by budget surplus.

The goal is to spend money, investing in society. Every dollar spent on education, healthcare, and science is an investment in our collective wellbeing.

Ugh. I hope they don’t pull funding from funded K99 MOSIAC peeps. It would be terrible if they suddenly couldn’t get their R00 phase money.

Reposted by Sarah Mitchell

Exciting news! MBL has received a $2.6M gift from an anonymous donor! This generous support fuels our mission of discovery, education, and innovation. Private philanthropy drives groundbreaking research and shapes the future of science. 🌎🔬 #ScienceStartsHere #Philanthropy
Today is Retraction Day, when we observe the anniversary of the retraction (Feb. 2, 2010) of the fraudulent paper that purported to show a link between vaccines and autism. 🧪#medsky